Compare Hewlett Packard Enterprise Co (HPE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

HPE stock trades at $72.115, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand and a recent $1.2 billion server order from Vultr. The technical outlook is bullish, with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth accelerated to $34.3 billion in 2025, but net income margin compressed to 0.16% due to higher costs, while 2026 projections show a rebound to $41.9 billion revenue and $2.8 billion net income.

The outlook remains positive given AI-driven guidance raises and analyst upgrades, but risks include execution on Juniper integration, debt levels rising to 29.48% of assets, and valuation multiples above sector averages. The stock offers growth exposure to AI infrastructure, yet investors face volatility near record highs.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.